Australia markets closed

Nuheara Limited (NUH.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.12000.0000 (0.00%)
At close: 04:10PM AEST
Full screen
Previous close0.1200
Open0.1150
Bid0.1150 x 197574900
Ask0.1100 x 26031200
Day's range0.1100 - 0.1200
52-week range0.1000 - 0.9800
Volume51,478
Avg. volume201,273
Market cap12.034M
Beta (5Y monthly)1.94
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Nuheara Announces New US-Based CEO and Engagement of Roth Capital Partners to Explore US Listing

    BELLEVUE, Wash., May 09, 2022 (GLOBE NEWSWIRE) -- Medical device manufacturer, Nuheara Limited (ASX:NUH) (Company or Nuheara) is pleased to announce a series of structural changes designed to advance the Company’s unique and growing US based hearing healthcare market opportunities: The appointment of John R. Luna as its global, US based, Chief Executive Officer;Co-founder and former CEO, Justin Miller, remaining as the Company’s Managing Director;Engagement of Roth Capital Partners LLC (“Roth”)

  • GlobeNewswire

    Nuheara Submits 510(k) for U.S. FDA Clearance

    BELLEVUE, Wash., April 12, 2022 (GLOBE NEWSWIRE) -- Nuheara Limited (ASX:NUH) (Company or Nuheara) has taken the final step in its plans to secure U.S. Food and Drug Administration (FDA) clearance for its self-fitting hearing aid by providing its 510(k) submission to the FDA. This follows completion of Nuheara’s successful clinical trial by National Acoustic Laboratories (NAL) in January 2022. The trial successfully validated the effectiveness of the Nuheara self-fitted hearing aids compared to

  • GlobeNewswire

    Nuheara Welcomes Landmark FDA Proposed Rules for Over-the-Counter Hearing Aids

    Nuheara is already undertaking clinical trials of a self-fit hearing aid and plans to file a 510(k) to launch one of the first products availableSAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nuheara (ASX: NUH), the developer of smart and affordable hearing solutions that transform the way people hear, welcomes the U.S. Food and Drug Administration (FDA) issuing its landmark proposal intended to improve access to and reduce the cost of hearing aid technology for millions of Americans[1]. The U